Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 5/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17824702 | 0.78 | PARG (0.61) | PARGPIK3CGTAS2R14PKMHTT | |
| SCHEMBL13819109 | 0.77 | PARG (0.54) | PARGPIK3CGTAS2R14PKMHTT | |
| SCHEMBL17825042 | 0.67 | ATM (0.56) | PARGPIK3CGPKMHTTLMNA | |
| SCHEMBL17832062 | 0.66 | PIK3CG (0.72) | PARGPIK3CGTAS2R14PKMHTT | |
| SCHEMBL9042836 | 0.65 | EPAS1 (0.32) | HTTLMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL17824893 | 0.65 | PARG (1.00) | PARG | |
| SCHEMBL6799654 | 0.63 | FEN1 (0.54) | PARGPIK3CGPKMHTTLMNA | |
| SCHEMBL17242614 | 0.63 | MEN1 (0.46) | PKMHTTLMNATP53SMN1; SMN2 | |
| SCHEMBL21848174 | 0.61 | ESR2 (0.33) | PARG | |
| SCHEMBL6389543 | 0.60 | PIK3CG (0.55) | PARGPIK3CGTAS2R14PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | PARG 1/4885PIK3CG 2127/4885TAS2R14 2882/4885 |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | PARG, PARP15, PARP12 | PARG 1/4885PIK3CG 2127/4885TAS2R14 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.